SEC Company Response from KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514) (KPRX) — Jun 6, 2017

KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514)
Date: June 6, 2017 · CIK: 0001372514 · Accession: 0001144204-17-031254

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-217418

Date

June 6, 2017

Author

H.C. WAINWRIGHT & CO., LLC

Form

CORRESP

Company

KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514)

Letter

Re: EyeGate Pharmaceuticals, Inc.

June 6, 2017

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, DC 20549

Registration Statement on Form S-1 (Registration No. 333-217418) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by EyeGate Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:00 P.M. (Washington, D.C. time), or as soon as practicable thereafter, on June 8, 2017, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,
H.C. WAINWRIGHT & CO., LLC

Show Raw Text

CORRESP
1
filename1.htm

June 6, 2017

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, DC 20549

 Re: EyeGate Pharmaceuticals, Inc.

Registration Statement on Form
S-1 (Registration No. 333-217418) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright &
Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by EyeGate
Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:00 P.M. (Washington,
D.C. time), or as soon as practicable thereafter, on June 8, 2017, pursuant to Rule 461 under the Securities Act. Wainwright affirms
that it is aware of its obligations under the Securities Act in connection with this offering.

    Very truly yours,

    H.C. WAINWRIGHT & CO., LLC

    By:
    /s/
    Mark W. Viklund

    Name: Mark W. Viklund

    Title: Chief Executive Officer

      430 Park Avenue | New York, New York 10022 | 212.356.0500

Security services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC

SecProbe.io